GLSI - NASDAQ
Greenwich LifeSciences, Inc.
$24.29
-15%Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
At a Glance
Live SnapshotNo Revenue Data
GLSI has not reported any revenue values in the available annual periods.
Greenwich LifeSciences, Inc. Profit Bridge
Profitability Analysis
Greenwich LifeSciences, Inc. Income Statement
GLSI • NASDAQ
| Greenwich LifeSciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
GROSS PROFIT | |||||||||
(1.8K) | (3.6K) | (3.6K) | (3.6K) | (3.6K) | (3.6K) | (3.6K) | (3.6K) | (3.6K) | |
-1.8K | -3.6K | -3.6K | -3.6K | -3.6K | -3.6K | -3.6K | -3.6K | -3.6K | |
OPERATING INCOME | |||||||||
(19.4M) | (16M) | (9.3M) | (8M) | (4.6M) | (1.9M) | (3.4M) | (1.7M) | (1.6M) | |
(2.2M) | (3.1M) | (1.6M) | (1.6M) | (1M) | (806.2K) | (818.9K) | (419.6K) | (346.8K) | |
(17.2M) | (13M) | (7.7M) | (6.5M) | (3.6M) | (1.1M) | (2.6M) | (1.3M) | (1.2M) | |
-19.4M | -16M | -9.3M | -8M | -4.6M | -1.9M | -3.4M | -1.7M | -1.6M | |
PRE-TAX INCOME | |||||||||
89.7K | 223K | 436.1K | 215K | 27.4K | 832.0 | 0.0 | 0.0 | 0.0 | |
89.7K | 223K | 436.1K | 215K | 27.4K | 832.0 | 0.0 | 0.0 | 0.0 | |
-19.4M | -15.8M | -8.9M | -7.8M | -4.6M | -1.9M | -3.4M | -1.7M | -1.6M | |
NET INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.0) | (0.0) | (3.0) | |
-19.4M | -15.8M | -8.9M | -7.8M | -4.6M | -1.9M | -3.4M | -1.7M | -1.6M |
SEC Filings
GLSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | June 04, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | June 01, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 24, 2025 | July 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 20, 2025 | March 31, 2025 | 2025 | |
10-K 10-K 2024 FY FY | April 15, 2025 | December 31, 2024 | 2024 | |
8-K 8-K 2024 N/A | December 19, 2024 | December 19, 2024 | 2024 |
Related Guides
Continue your GLSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.